Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N03 ANTIEPILEPTICS
N03A ANTIEPILEPTICS
N03AX Other antiepileptics
N03AX27 Ganaxolone
D04300 Ganaxolone (USAN/INN) <US>
USP drug classification [BR:br08302]
Anticonvulsants
Gamma-aminobutyric Acid (GABA) Augmenting Agents
GABA Agents, Other
Ganaxolone
D04300 Ganaxolone (USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02919 CYP2B6 substrate
D04300 Ganaxolone
DG01639 CYP2C19 substrate
D04300 Ganaxolone
DG01644 CYP2D6 substrate
D04300 Ganaxolone
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D04300 Ganaxolone
DG02925 CYP3A5 substrate
D04300 Ganaxolone
Target-based classification of drugs [BR:br08310]
Ion channels
Ligand-gated ion channels
GABA (ionotropic)
GABR
D04300 Ganaxolone (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04300
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04300
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04300
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04300
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D04300